The DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.
OX40 is required for regulatory T cell–mediated control of colitis
Open accessAbstract
The immune response in the gastrointestinal tract is a tightly controlled balance between effector and regulatory cell responses. Here, we have investigated the role of OX40 in influencing the balance between conventional T cells and Foxp3+ regulatory T (T reg) cells. Under steady-state conditions, OX40 was required by T reg cells for their accumulation in the colon, but not peripheral lymphoid organs. Strikingly, under inflammatory conditions OX40 played an essential role in T reg cell–mediated suppression of colitis. OX40−/− T reg cells showed reduced accumulation in the colon and peripheral lymphoid organs, resulting in their inability to keep pace with the effector response. In the absence of OX40 signaling, T reg cells underwent enhanced activation-induced cell death, indicating that OX40 delivers an important survival signal to T reg cells after activation. As OX40 also promoted the colitogenic Th1 response, its expression on T reg cells may be required for effective competition with OX40-dependent effector responses. These results newly identify a key role for OX40 in the homeostasis of intestinal Foxp3 +T reg cells and in suppression of colitis. These fi ndings should be taken into account when considering OX40 blockade for treatment of IBD.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Koch, M. A., Tucker-Heard, G., Perdue, N. R., Killebrew, J. R., Urdahl, K. B., & Campbell, D. J. (2009) · Nature Immunology · doi:10.1038/ni.1731 · Cited by 1,258
Powrie, F., Leach, M. W., Mauze, S., Menon, S., Barcomb Caddle, L., & Coffman, R. L. (1994) · Immunity · doi:10.1016/1074-7613(94)90045-0 · Cited by 1,146 · cited 1×
“…in the total number of Foxp3+ T reg cells that accumulated after activation JEM VOL. 207, April 12, 2010 705 Br ief Definit ive Repor t These results show that OX40 expression by T cells promotes colitogenic Th1 responses, which are known to drive colitis in this model (Powrie et al., 1994).”
BackgroundSelf-citationCD4 + Regulatory T Cells Control T H 17 Responses in a Stat3-Dependent Manner
Chaudhry, A., Rudra, D., Treuting, P., Samstein, R. M., Liang, Y., Kas, A., & Rudensky, A. Y. (2009) · Science · doi:10.1126/science.1172702 · Cited by 1,000 · cited 1×
“Thus, to inhibit Th1, Th2, or Th17 responses, T reg cells need to express T-bet (Koch et al., 2009), IRF-4 (Zheng et al., 2009), and Stat3 (Chaudhry et al., 2009), respectively.”
BackgroundRegulatory T-cell suppressor program co-opts transcription factor IRF4 to control TH2 responses
Zheng, Y., Chaudhry, A., Kas, A., deRoos, P., Kim, J. M., Chu, T.-T., Corcoran, L., Treuting, P., Klein, U., & Rudensky, A. Y. (2009) · Nature · doi:10.1038/nature07674 · Cited by 958
Central Role of Defective Interleukin-2 Production in the Triggering of Islet Autoimmune Destruction
Tang, Q., Adams, J. Y., Penaranda, C., Melli, K., Piaggio, E., Sgouroudis, E., Piccirillo, C. A., Salomon, B. L., & Bluestone, J. A. (2008) · Immunity · doi:10.1016/j.immuni.2008.03.016 · Cited by 729
Cited by
Intestinal homeostasis and its breakdown in inflammatory bowel disease
Maloy, K. J., & Powrie, F. (2011) · Nature · doi:10.1038/nature10208 · Cited by 1,870
Self-citationRegulatory T cells in cancer immunosuppression — implications for anticancer therapy
Togashi, Y., Shitara, K., & Nishikawa, H. (2019) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-019-0175-7 · Cited by 1,546
Proinflammatory Cytokines in the Pathogenesis of Inflammatory Bowel Diseases
Strober, W., & Fuss, I. J. (2011) · Gastroenterology · doi:10.1053/j.gastro.2011.02.016 · Cited by 1,102
Guidelines for the use of flow cytometry and cell sorting in immunological studies (second edition)
Cossarizza, A., Chang, H., Radbruch, A., Acs, A., Adam, D., Adam‐Klages, S., Agace, W. W., Aghaeepour, N., Akdis, M., Allez, M., et al. (2019) · European Journal of Immunology · doi:10.1002/eji.201970107 · Cited by 979
The future of cancer treatment: immunomodulation, CARs and combination immunotherapy
Khalil, D. N., Smith, E. L., Brentjens, R. J., & Wolchok, J. D. (2016) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2016.25 · Cited by 929
The microbiome in infectious disease and inflammation
Honda, K., & Littman, D. R. (2012) · Annual Review of Immunology · doi:10.1146/annurev-immunol-020711-074937 · Cited by 791
Experimental Models of Inflammatory Bowel Diseases
Kiesler, P., Fuss, I. J., & Strober, W. (2015) · Cellular and Molecular Gastroenterology and Hepatology · doi:10.1016/j.jcmgh.2015.01.006 · Cited by 713
Development and maintenance of intestinal regulatory T cells
Tanoue, T., Atarashi, K., & Honda, K. (2016) · Nature Reviews Immunology · doi:10.1038/nri.2016.36 · Cited by 553
GATA3 controls Foxp3+ regulatory T cell fate during inflammation in mice
Wohlfert, E. A., Grainger, J. R., Bouladoux, N., Konkel, J. E., Oldenhove, G., Ribeiro, C. H., Hall, J. A., Yagi, R., Naik, S., Bhairavabhotla, R., et al. (2011) · Journal of Clinical Investigation · doi:10.1172/jci57456 · Cited by 556
Guidelines for the use of flow cytometry and cell sorting in immunological studies (third edition)
Cossarizza, A., Chang, H., Radbruch, A., Abrignani, S., Addo, R., Akdis, M., Andrä, I., Andreata, F., Annunziato, F., Arranz, E., et al. (2021) · European Journal of Immunology · doi:10.1002/eji.202170126 · Cited by 531
Roles of regulatory T cells in cancer immunity
Takeuchi, Y., & Nishikawa, H. (2016) · International Immunology · doi:10.1093/intimm/dxw025 · Cited by 523
Resolution of chronic inflammatory disease: universal and tissue-specific concepts
Schett, G., & Neurath, M. F. (2018) · Nature Communications · doi:10.1038/s41467-018-05800-6 · Cited by 427
Chen, X., Wu, X., Zhou, Q., Howard, O. M. Z., Netea, M. G., & Oppenheim, J. J. (2013) · The Journal of Immunology · doi:10.4049/jimmunol.1202659 · Cited by 293
OX40, OX40L and Autoimmunity: a Comprehensive Review
Webb, G. J., Hirschfield, G. M., & Lane, P. J. L. (2016) · Clinical Reviews in Allergy & Immunology · doi:10.1007/s12016-015-8498-3 · Cited by 277
The immunobiology of CD27 and OX40 and their potential as targets for cancer immunotherapy
Buchan, S. L., Rogel, A., & Al-Shamkhani, A. (2018) · Blood · doi:10.1182/blood-2017-07-741025 · Cited by 276
Therapeutic strategies for the costimulatory molecule OX40 in T-cell-mediated immunity
Fu, Y., Lin, Q., Zhang, Z., & Zhang, L. (2020) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2019.08.010 · Cited by 260
Piconese, S., Timperi, E., Pacella, I., Schinzari, V., Tripodo, C., Rossi, M., Guglielmo, N., Mennini, G., Grazi, G. L., Di Filippo, S., et al. (2014) · Hepatology · doi:10.1002/hep.27188 · Cited by 81
Metadata
- Authors
- Griseri, T., Asquith, M., Thompson, C., & Powrie, F.
- Venue
- Journal of Experimental Medicine
- Publisher
- Rockefeller University Press
- Published
- 2010-04-05
- Volume
- 207
- Issue
- 4
- Pages
- 699-709
- ISSN
- 0022-1007 (ISSN-L)
- 1540-9538
- OpenAlex
- W2109057661
- Cited by
- 160
- References
- 5
- FWCI
- 5.15
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.